A Phase 1, Multicenter, Open-label Study of REM-422, a MYB MRNA Degrader, in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carci...